Paragon 28 To Report First Quarter Financial Results on May 4, 2023

Rhea-AI Summary

Paragon 28, Inc. (NYSE: FNA), a prominent medical device company focusing on the foot and ankle orthopedic market, will announce its first quarter 2023 financial results on May 4, 2023, after market close. A conference call is scheduled for 4:30 p.m. ET, providing insights into the company's financial performance and future outlook. Investors can join the call by dialing (833-470-1428) domestically or (929-526-1599) internationally, using conference ID: 007721. The event will also be webcasted live on the company's investor website, with a replay available for 90 days. Paragon 28 is dedicated to enhancing patient care through innovative orthopedic solutions for various foot and ankle conditions, aiming to improve surgical outcomes and reduce complications.

ENGLEWOOD, Colo.--(BUSINESS WIRE)-- Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the first quarter 2023 after market close on Thursday, May 4, 2023. The company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time.

Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (929-526-1599) for international callers, using conference ID: 007721. Live audio of the webcast will be available on the “Investors” section of the company’s website at: ir.paragon28.com. The webcast will be archived and available for replay for at least 90 days after the event.

About Paragon 28, Inc.

Based in Englewood, Colo., Paragon 28, is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230420005063/en/

Investor Contact:

Matthew Brinckman

Senior Vice President, Strategy and Investor Relations

Phone: (720) 912-1332

mbrinckman@paragon28.com

Source: Paragon 28, Inc.

FAQ

When will Paragon 28 report its financial results for Q1 2023?

Paragon 28 will report its financial results for the first quarter of 2023 after market close on May 4, 2023.

What time is the conference call for Paragon 28's Q1 results?

The conference call for Paragon 28's Q1 results is scheduled for 4:30 p.m. Eastern Time on May 4, 2023.

How can I listen to the Paragon 28 conference call?

Investors can listen to the Paragon 28 conference call by dialing (833-470-1428) for domestic calls or (929-526-1599) for international calls, using conference ID: 007721.

Where will the webcast of Paragon 28's conference call be available?

The live audio of Paragon 28's conference call will be available on the 'Investors' section of the company's website at ir.paragon28.com.